Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
News
$ 43.15
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Data is available to registered users only
Target Price
The average target price of SRRK is 48 and suggests 12% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation su
Data is available to registered users only
Buy
Sell